30 C
Vientiane
Monday, November 3, 2025
spot_img
Home Blog Page 1481

ESG Xchange 2025 | The Premier Global ESG and Innovation Summit in Hong Kong

Sign up for FREE PASS : https://esgxchangehk.com/register


HONG KONG SAR – Media OutReach Newswire – 23 April 2025 – The World Green Organisation (WGO) proudly presents ESG Xchange 2025, set to take place on May 6–7, 2025 at Hall 5G, Hong Kong Convention and Exhibition Centre (HKCEC). This international flagship summit will bring together over 2,500 global leaders from the fields of ESG, climate finance, sustainable development, and technology innovation.

ESG Xchange 2025

This two-day summit is designed to unite high-level stakeholders, industry leaders, and innovators to drive transformative actions in sustainability and environmental, social, and governance (ESG) practices.

Event Overview
The theme of this year’s event is Sustainability, ESG and Carbon Neutrality, Conference Partners and Key Supporting Orgnisations such as United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), Hong Kong Stock Exchanges (HKEX), Financial Services Development Council (FSDC), Cyberport, Securities and Futures Commission (SFC) and United Nations Environment Programme Finance Initiative (UNEP FI). With a focus on fostering global sustainable development, the summit aims to empower enterprises in achieving green transformation, advance green finance, and enhance regional collaboration.

ESG Xchange 2025 -highlights

Key Highlights of the Summit

1. International Thought Leadership Platform
Featuring speakers from ISSB, UNEP FI, TNFD, and GRI, alongside global corporate executives and policy advisors, the Main Stage and Pavilion Stages will address ESG regulatory trends, disclosure standards, and strategic foresight.

2. Technology & Innovation Exhibition Zone
Showcasing over 30 local and international tech ventures in areas such as carbon neutrality, ESG data, smart cities, AI-powered sustainability, and green supply chain management.

3.
Business Matching & Market Expansion Opportunities
A dedicated Networking & Matchmaking Lounge will connect participants with investors, corporate buyers, accelerators, and market advisors from the Middle East, ASEAN, Europe, and Mainland China.

4. Thematic Program Tracks

  • “Going Global” Strategy Forum for outbound enterprises
  • “Cambridge Session” on navigating the European ESG and compliance landscape
  • AI and Climate Tech Pitching Sessions
  • Youth Climate Leadership Forum and the Global Carbon Neutrality Campus Alliance Exchange


Core Attendee Profiles

  • 20–30 top Mainland Chinese enterprises and over 200 representatives from Hong Kong listed companies across key industries
  • Business diplomats from foreign consulates in Hong Kong
  • Strategic and international business development teams
  • Technology startups and R&D innovators
  • Asset managers, ESG investors, and sustainable finance professionals
  • International and regional chambers of commerce
  • Academia and climate-focused university alliances (Carbon Neutrality leaders from top universities across Japan, Malaysia, Thailand, and Indonesia, sharing insights on low-carbon transition and campus sustainability strategies)
  • NGOs and youth advocates engaged in social innovation

Participants can expect engaging discussions with global leaders, keynote speeches, and specialized workshops on crucial topics such as climate risk modeling, green finance standards, and digital ESG solutions.

Impact of Previous Events
ESG Xchange has established itself as a vital platform over the past years, successfully bringing together diverse stakeholders to collaborate on sustainable solutions. The previous edition attracted over 1,000 participants, including C-suite executives and key decision-makers, demonstrating its significance in the ESG landscape.

Be Part of the Change
ESG Xchange 2025 is more than a summit — it is a dynamic platform to network, co-create, and transform. Whether you’re a business leader, policymaker, investor, or startup founder, this event offers unmatched access to ESG strategies, technologies, and global business opportunities.

Date: May 6–7, 2025
Time: 9 A.M – 6 P.M.
Venue: Hall 5G, Hong Kong Convention and Exhibition Centre (HKCEC)
Register Now: https://esgxchangehk.com/register

Don’t miss your chance to be part of this transformative event. For more information and to register, please visit ESG Xchange 2025.

Hashtag: #WGO #ESG #Innovation #Sustainability #CarbonNeutrality #ESGXCHANGE2025 #Internationalsummit #HKCEC #UNESCAP #HKEX #FSDC #Cyberport #SFC #ISSB #UNEPFI #TNFD #GRI #TNFD #SBTi #CDP #MSCI




The issuer is solely responsible for the content of this announcement.

World Green Organisation

The World Green Organisation (WGO) is an independent non-governmental organization dedicated to environmental conservation and promoting sustainable development. Through science-based public policies, community projects, and partnerships, WGO aims to improve the economy, the environment, and livelihoods, ensuring a brighter, more sustainable future for all sectors of society.

For more details about the event and sponsorship opportunities, please visit:

Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA

ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg, and 40 mg doses.

ASC30 oral once-daily tablet also demonstrated a 4.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 5 mg, 10 mg, and 20 mg doses. No vomiting was seen in this dose group.

Data from three different weekly titration schemes in the Phase Ib trial support utilizing a “lower starting dose and slower titration strategy for a 13-week Phase IIa study design of ASC30 oral once-daily tablet.

HONG KONG, April 23, 2025 /PRNewswire/ — Ascletis Pharma Inc. (HKEX:1672, “Ascletis”) announces today positive topline results of its randomized, double-blind, placebo-controlled Phase Ib multiple ascending dose (MAD) study (NCT06680440), conducted in the U.S., of ASC30 oral once-daily tablet in participants with obesity (body mass index (BMI): 30-40 kg/m2). The Phase Ib MAD study consisted of three cohorts, each with a different weekly titration scheme, for a total of four-week treatment and one-week follow up. Scheme 1 (mid starting dose, slow titration: 2 mg, 5 mg, 10 mg, and 20 mg); Scheme 2 (mid starting dose, normal titration: 2 mg, 10 mg, 20 mg, and 40 mg); and Scheme 3 (high starting dose, fast titration: 5 mg, 15 mg, 30 mg, and 60 mg).  Based on single ascending dose (SAD) data in participants with obesity, Schemes 1 and 2 were designed to investigate tolerability and efficacy. All participants with obesity stayed at the clinical site from day 1 to day 2 and from day 27 to day 29. For other days during the study, participants maintained their habitual eating and physical activity patterns as out-patients.

Mean body weight reductions from baseline for Scheme 1 (mid starting dose, slow titration: 2 mg, 5 mg, 10 mg, and 20 mg) and Scheme 2 (mid starting dose, normal titration: 2 mg, 10 mg, 20 mg, and 40 mg) were 4.3% (n=7, p=0.0002 vs placebo) and 6.3% (n=8, p<0.0001 vs placebo), respectively, after four-week treatment. No weight plateau was observed. Mean body weight increase from baseline for placebo was 0.2% (n=6, two placebos from each of three schemes). Placebo adjusted mean body weight reductions for Schemes 1 and 2 from baseline were 4.5% and 6.5%, respectively. The maximum body weight reductions from baseline were 7.6% and 9.1% for Schemes 1 and 2, respectively. ASC30 oral once-daily tablet was generally safe and well tolerated among Schemes 1 and 2, with a favorable safety profile. The majority of gastrointestinal (GI)-related adverse events (AEs) were mild (Grade 1) and short-lived. Schemes 1 and 2 demonstrated improved or comparable GI tolerability to the GLP-1 class such as orforglipron. For example, Scheme 1 had no incidences of vomiting.

After reviewing the safety and efficacy results of the first two dosing schemes, a third dosing scheme (high starting dose, fast titration: 5 mg, 15 mg, 30 mg, and 60 mg) was designed to help validate the optimal combination of tolerability and efficacy seen in Schemes 1 and 2. Mean body weight reduction from baseline for Scheme 3 was 4.8% (n=7, p=0.0015 vs placebo) after four-week treatment. Placebo-adjusted mean body weight reduction from baseline was 5.0%. The maximum body weight reduction from baseline was 9.3%. In Scheme 3, there were two outliers, each with body weight reduction of 1.8% from baseline, which were not seen in Schemes 1 or 2.  Excluding these two outliers, placebo-adjusted mean body weight reduction from baseline in Scheme 3 was 6.1%, comparable to Scheme 2. The maximum body weight reduction from baseline of Scheme 3 was also comparable to Scheme 2 (9.3% and 9.1%, respectively). Moreover, the GI tolerability observed in Scheme 3 was less than that of Schemes 1 and 2, due to its high starting dose, fast titration design.

For all the above mentioned three schemes, no serious adverse events (SAEs) were reported. There were no Grade 3 or higher AEs including GI-related AEs observed. There were no elevations of liver enzymes including alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin (TBL) during the treatment. There were no abnormal findings in laboratory tests, vital signs, ECGs (electrocardiograms, including QTc intervals), and physical exams.

Both tolerability and efficacy data from the ASC30 tablet Phase Ib study support a “lower starting dose and slower titration” strategy for a 13-week Phase IIa study design of ASC30 oral once-daily tablet. The 13-week Phase IIa study protocol, which has a low starting dose and slow weekly titration to the desired maintenance doses, has been submitted to the U.S. Food and Drug Administration (FDA) following a preliminary consultation with FDA.  The Company expects to initiate the 13-week Phase IIa study in the U.S. at the beginning of the third quarter of 2025.

ASC30 was discovered and developed in-house at Ascletis as a first and only investigational small molecule GLP-1 receptor (GLP-1R) biased agonist designed to be dosed once daily orally and once monthly subcutaneously for the treatment of obesity.

“We are excited that these topline results from our Phase Ib study demonstrated potential best-in-class characteristics to treat obesity,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. “Results from the Phase Ib study in U.S. informed and provided critical knowledge for our 13-week Phase IIa study design of ASC30 oral once-daily tablet. As a small molecule, ASC30 has the potential to offer both once-daily oral and once-monthly subcutaneous injection dosing options for obesity treatment, if approved.”

About ASC30

ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044. 

About Ascletis Pharma Inc.

Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline.

For more information, please visit www.ascletis.com.

Contact: 

Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com

Ascletis Pharma Inc. PR and IR teams
+86-181-0650-9129 (China)
pr@ascletis.com
ir@ascletis.com 

SK hynix Completes Customer Validation of CXL 2.0-based DDR5

  • Completion of customer qualification of 96GB product to help customers reduce costs when applied to server systems
  • 128GB product of improved performance, equipped with 1bnm 32Gb DDR5, also in customer validation process
  • Company to provide value unmatched by others through “Optimal Innovation”

SEOUL, South Korea, April 23, 2025 /PRNewswire/ — SK hynix Inc. (or “the company”, www.skhynix.com) announced today that it has completed customer validation of 96GB CMM(CXL[1] Memory Module)-DDR5, a DRAM solution product based on CXL 2.0.

1 Compute eXpress Link (CXL): A next-generation interface that efficiently connects CPU, GPU, memory, and other components in high-performance computing systems to support massive, ultra-fast computation. Based on PCIe interface, CXL allows fast data transfer and has pooling capability to efficiently utilize memory

The company said that it can process 36GB/s due to a 50% increase in capacity when the product is applied to the server systems and a 30% improvement in the bandwidth compared to previous DDR5 modules. This can contribute to drastically reducing the total cost of ownership[2] by customers in building and operating data centers.

2 Total cost of ownership: Total cost of owning a product or service, from purchase to disposal. It also includes costs for deployment, maintenance, operations and upgrades

Following the 96GB product validation, the company is proceeding with the validation process for 128GB product with another customer. This product, equipped with 32Gb DDR5 DRAM using the 1bnm process, or the fifth-generation of the 10-nanometer technology, has high performance per watt[3]. The company plans to complete the ongoing 128GB validation as soon as possible to establish a CXL product portfolio to support customers in a timely manner.

3 Performance per watt: Indicator of data capacity per second that can be processed per unit of power

SK hynix is making efforts to expand the CXL ecosystem along with the development of CXL DRAM. The company developed HMSDK[4], software optimized for CMM-DDR5 and integrated it on Linux, the world’s largest open-source operating system, in September, improving the performance of CXL applied systems.

4 Heterogeneous Memory S/W Development Kit (HMSDK): SK hynix’s unique development kit for heterogeneous memory software. It improves performance by expanding bandwidth through efficient crossbar array and rearranging data with appropriate memory device in accordance with data use frequency.

“We are developing various solution products to fulfill Optimal Innovation[5] in order to overcome the limitation of high cost and scalability of the existing system,” said Uksong Kang, Head of Next Gen PP&E. “We will provide optimized value to customers by dramatically improving the scalability and the flexibility of memory while meeting customers’ different needs.”   

5 Optimal Innovation: One of the product orientations unveiled by SK hynix at the SK AI Summit 2024, meaning product innovation optimized for AI era systems such as CXL and PIM

About SK hynix Inc.

SK hynix Inc., headquartered in Korea, is the world’s top tier semiconductor supplier offering Dynamic Random Access Memory chips (“DRAM”) and flash memory chips (“NAND flash”) for a wide range of distinguished customers globally. The Company’s shares are traded on the Korea Exchange, and the Global Depository shares are listed on the Luxembourg Stock Exchange. Further information about SK hynix is available at www.skhynix.com, news.skhynix.com.

Mary is born: The New iOS Super App That Puts Generative AI at Your Fingertips

MILAN, April 23, 2025 /PRNewswire/ — Now available on the App Store, https://apps.apple.com/app/mary-ai-assistente-e-chat/id6740776978, Mary is the groundbreaking mobile app that brings the full power of artificial intelligence into your pocket. Designed for creatives, professionals, and curious minds, Mary offers an all-in-one AI suite directly on your smartphone.

Images showcasing Mary’s main AI features
Images showcasing Mary’s main AI features

Multi-Model AI at Your Fingertips

Mary gives users the freedom to choose between top AI models like ChatGPT, Mistral, Llama, and Gemma. Whether you’re writing, brainstorming, or solving complex problems, you can compare answers and select the best tool for your task — all within a single app.

Images, Videos, and Music – Powered by AI

Mary goes beyond text. Create high-definition images using advanced models like Flux, Stable Diffusion, and Recraft.

Riding the latest AI image trends, Mary stands out with unique generation styles including Ghibli-inspired art and action figure-style characters — letting users create whimsical, cinematic, or collectible-style visuals with ease.

For video creation, Mary integrates the Kling platform to generate stunning AI-powered animations, with more models on the way. Music lovers can compose custom tracks by selecting lyrics, genres, and instruments, turning creative ideas into original songs.

Smart Lens: See the World Differently

Mary’s smart lens uses AI to recognize and analyze QR codes, plants, animals, insects, foods, collectible coins, and even celebrities. It goes beyond identification — offering practical insights like food composition analysis in real time.

AI Keyboard & Intelligent Editing

The built-in AI keyboard allows for real-time translation and grammar correction in any language — perfect for smooth, multilingual communication.

Photo lovers can enhance their images with a Photo Enhancer or erase unwanted elements using the Magic Eraser, all with just a tap.

Mary is available now on the App Store. Unlock your creativity and experience the future of AI on mobile: https://apps.apple.com/app/mary-ai-assistente-e-chat/id6740776978

About Mary Srl
Mary Srl is an Italian startup focused on making cutting-edge AI intuitive and accessible. With years of experience in mobile development, the team blends Italian creativity with world-class innovation to shape smarter digital experiences — starting with Mary.

Media Contact:
Francesco Contino
Phone number: / +39 3514194710
Email address: info@thinktorise.app

 

FDA Grants Authorisation for Minder®, the First and Only Implantable Continuous EEG Monitor Approved in US

  •  The Australian-developed Minder system is an implantable device for continuous monitoring of brain activity in patients with epilepsy, developed to address the shortcomings in current electroencephalogram technologies
  •  The FDA has granted authorisation for Minder under its De Novo pathway creating a new classification of device, allowing for marketing and sale of the device in the US for patients with drug resistant epilepsy
  •  Epiminder intends to launch Minder in the US during H2 2025

MELBOURNE, Australia and DALLAS, April 23, 2025 /PRNewswire/ — Epiminder, a pioneering medical device and information solutions company, today announced that it has been granted FDA authorisation via the De Novo classification for Minder, its proprietary implantable continuous electroencephalogram monitoring system (iCEMTM) for patients with epilepsy.  Minder has also been designated as a Breakthrough Technology by the FDA, recognising its potential to provide more effective diagnosis and management for people living with epilepsy. This De Novo authorization is significant as it creates a new classification of device which underscores both the innovation and the clinical validation behind Minder.

Without accurate diagnosis and monitoring, sustained and effective management of epilepsy can be challenging.  Minder has been developed to address the shortcomings in current electroencephalogram (EEG) technologies, providing reliable and actionable diagnostic data for more patients and therefore better enabling their prospects for successful epilepsy treatment. 

Rohan Hoare PhD, CEO of Epiminder, said: ” By extending the monitoring window of an EEG from days using current technologies to months or even years with Minder, we can deliver unprecedented access to a high-fidelity stream of continuous EEG data to health care professionals and their patients.

The FDA’s clearance of Minder is a significant milestone for Epiminder and more importantly for the 52 million people around the world who have epilepsy.  As the first and only implantable continuous EEG monitor approved in US, Minder can provide health care professionals and their patients with more accurate and timely diagnoses, enhanced therapeutic drug monitoring, and can better inform decisions on non-drug treatments like surgery.

Looking ahead, Epiminder plans to develop a suite of integrated software solutions that will extend the clinical impact of the Minder device, for example by providing patients with advance notice of seizures through AI-enabled forecasting.”

Epiminder intends to formally launch Minder in the US during H2 2025 undertaking a phased commercial roll out into leading epilepsy centres as part of a program to demonstrate the clinical utility of the system.

Professor Robert Fisher MD, PhD, Director of the Stanford Epilepsy Center, past-President of the American Epilepsy Society, and Chair of the Data Safety Monitoring Board for the UMPIRE trial, said: “One of the greatest difficulties in caring for people with epilepsy is the lack of accurate information about a patient’s seizures. Seizure diaries are of limited effectiveness. Minder can greatly improve seizure tracking and therefore seizure management. It will fill the significant gap in current EEG technologies, providing clinicians like me continuous and accurate data. By having a more complete picture, we can be more precise in our diagnoses, better able to rapidly adjust medication or neuromodulation regimens and identify patients for potential non-drug or surgical treatments. The result will be a reduction in the huge burden of drug resistant epilepsy.”

The safety and effectiveness of Minder was validated through Epiminder’s UMPIRE clinical study, a multi-centre prospective, open design, case-controlled comparator trial that was undertaken in leading Australian hospitals between 2019 and 2023.  The results of UMPIRE were used to support Epiminder’s successful FDA application.

Professor Mark Cook MD MBBS FRACP FRCP (London), Epiminder’s Founder and Chief Medical Officer, said: “The results from UMPIRE exceeded our expectations and demonstrated Minder’s ability to capture high-quality EEG data continuously for extended periods, including a groundbreaking five-year continuous recording in one participant.  Minder delivered actionable clinical insights for nearly 90 percent of study participants, highlighting the real-life benefits that Epiminder’s best-in-class iCEM can deliver relative to the current standard of care.”

Epilepsy is one of the most common serious chronic neurological disorders, affecting approximately 52 million people worldwide including 250,000 Australians and 3.4 million Americans. It is a neurological condition where a person experiences recurrent seizures caused by abnormal electrical activity in the brain.  Seizures can present with a variety of clinical manifestations; some involve motor symptoms, such as intense muscle contractions, while others, such as absence or focal impaired awareness seizures, may present with subtle or no outward physical signs.  The occurrence of seizures varies in frequency among patients, from less than one a year to several a day.

Follow Epiminder on LinkedIn and explore www.epiminder.com for more information.

About Minder

Minder is a minimally invasive device for continuous monitoring of electrographic activity of the brain, providing epilepsy patients and their doctors with detailed data on brain activity over an extended period. Patients can wear the device as they go about their normal daily activities.

Minder’s long-term monitoring of patients outside of a controlled clinical environment provides data needed for better understanding and more effective treatment of underlying conditions, including determining the effectiveness of drug therapies and other potential interventions.

About Epiminder

Founded in 2017 by Professor Mark Cook together with the Bionics Institute, St Vincent’s Hospital, the University of Melbourne and Cochlear Limited. Epiminder is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy and other seizure disorders where continuous monitoring is required. Epiminder is headquartered in Melbourne, Australia and has offices in the United States.

Contact: Matt Wright, matt@nwrcommunications.com.au

Bizcap NZ reports back-to-back record months as demand for line of credit surges

AUCKLAND, New Zealand, April 23, 2025 /PRNewswire/ — Alternative lender Bizcap has recorded its biggest month yet in New Zealand, driven by a sharp rise in uptake of its Line of Credit product. The result follows a record-breaking February, with March originations climbing a further 4%, underlining sustained momentum across the country’s small business finance sector.

In a sign of growing demand for flexible, ongoing access to capital, 41% of all March deals in NZ were Line of Credit facilities, confirming strong product-market fit just months after launch.

“This level of uptake, so soon after releasing the product, validates what we’ve been hearing from advisers and SMEs: New Zealand businesses need simpler, faster ways to manage cash flow and snap up opportunities,” said Adam Szental, Chief Operating Officer at Bizcap. “And with major tech upgrades being launched—like our new Partner Portal—we’re making the experience even more seamless for advisers and their clients.”

Bizcap credits its recent growth in New Zealand to its fast decisioning, low-documentation model, and an adviser-first approach that includes lifetime commissions and dedicated local support. The company recently expanded its product offering with the launch of Bizcap Prime—a longer-term, lower-rate loan designed to give established SMEs even greater choice and flexibility.

To continue supporting adviser education and product awareness, Bizcap’s NZ General Manager Camilla Tumai has been hosting Line of Credit webinars for partners. Another session is scheduled for 2nd May, with registration via Eventbrite.

“We’re building strong relationships with New Zealand partners who value transparency, speed, and service,” said Camilla Tumai, NZ General Manager. “The growth we’ve seen is a shared success—our partners are at the centre of it.”

Bizcap launched in New Zealand in 2022 and has grown rapidly, offering funding up to $2 million with approvals in as little as three hours. Its Business Line of Credit product, introduced in 2024, offers businesses ongoing access to capital with flexible drawdowns, up to $500k in funding, with no need to reapply.

About Bizcap

Bizcap is a leading non-bank business lender operating across New Zealand, Australia, the United Kingdom and Singapore. Since launching in 2019, it has funded over 30,000 business loans totalling more than $1 billion, with a 4.8/5 Trustpilot rating. Bizcap partners with advisers and aggregators to deliver fast, flexible funding tailored to real-world business needs.

For more information, visit https://www.bizcap.nz/ 

HCLTech delivers another year of industry-leading growth

Fastest growth among peers for the second year in a row; Q4 new deal wins at $3B taking FY25 TCV to $9.3B

NEW YORK and NOIDA, India, April 23, 2025 /PRNewswire/ — HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2025.

The company continued its robust performance with FY25 revenue growing 4.3% to $13.84 billion. Deal pipeline continues to be strong and diversified with total new deal wins for the year at $9.3 billion. For FY26, the company has given a guidance of 2%-5% revenue growth YoY (CC) and EBIT margin at 18%-19%.    

“HCLTech grew the fastest among our peers for the second year in a row as we witnessed yet another year of disciplined execution. We delivered on our FY25 guidance with revenue growth of 4.7% in constant currency and EBIT margin of 18.3%. HCLSoftware growth continues to accelerate as it grew 3.5% CC this year. During this quarter, our services business delivered healthy growth of 0.7% QoQ CC amidst volatile market conditions. We saw very strong new bookings of $3 billion this quarter catalyzed by our AI propositions and integrated GTM organization that was set up at the start of the fiscal year. The strength of our execution should present us good medium-term opportunities emerging out of global uncertainties while we navigate the short-term cautiously,” said C Vijayakumar, CEO & Managing Director, HCLTech.

For FY25, Services revenue grew by 4.8% YoY (CC). Digital Services revenue grew by 8.6% YoY (CC) and now contributes 39% of Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.03 billion, up 1.8% CC.

Industry vertical growth was led by Telecommunications, Media, Publishing & Entertainment with 43.4% growth YoY (CC), followed by Retail and CPG at 10.7% YoY (CC) and Technology and Services at 6.7% YoY (CC).  In terms of geographies, Americas was the fastest growing region with 5.3% YoY (CC) growth, while Europe grew by 3.5% YoY (CC) and the Rest of the World grew by 4.7% YoY (CC).

HCLTech announced a dividend of ₹18/share for the fourth quarter, bringing the total to ₹60/share for FY25.

“HCLTech delivered 6.5% INR revenue growth in FY25, yet another year of best-in-class performance. Our revenue came in at ₹117,055 crores, up 6.5% and EBIT at ₹21,420 crores, up 7%. HCLTech service revenue crossed a new milestone at ₹105,398 crores, up 6.6%. Our Net Income (NI) for the year came in at ₹17,390 crores, up 10.8%, translating to an EPS of ₹64.09,” added Shiv Walia, Chief Financial Officer, HCLTech.

HCLTech remained a partner of choice for G2000 enterprises, thanks to its future-ready portfolio. Among the key deals that HCLTech won in the quarter are:

  • A US-based global hi-tech company selected HCLTech for a mega engineering services deal to serve the rapidly growing AI-powered silicon and software-defined vehicle segments.
  • HCLTech will enable Western Union’s transition to an AI-led platform operating model and will help it establish an advanced technology center in Hyderabad.
  • Carrix, the world’s largest independent marine and rail terminal operator, selected HCLTech to improve its global port operations with HCLTech’s advanced suite of AI Engineering and AIoT offerings.

Some of the key recognitions that HCLTech received in Q4 FY25 include: 

  • Named the world’s fastest-growing IT services brand in Brand Finance 2025 Global 500 and IT Services Top 25 report
  • Recognized as Global Top Employer for the third consecutive year by Top Employers Institute.
  • Named one of Ethisphere’s 2025 World’s Most Ethical Companies® for the second consecutive year.
  • Included in S&P Global Sustainability Yearbook for the third year in a row.

About HCLTech

HCLTech is a global technology company, home to more than 223,000 people across 60 countries, delivering industry-leading capabilities centered around digital, engineering, cloud and AI, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, Technology and Services, Telecom and Media, Retail and CPG and Public Services. Consolidated revenues as of 12 months ending March 2025 totaled $13.8 billion. To learn how we can supercharge progress for you, visit hcltech.com.

For further details, please contact:

Meredith Bucaro, Americas
meredith-bucaro@hcltech.com

Elka Ghudial, EMEA
elka.ghudial@hcltech.com 

James Galvin, APAC
james.galvin@hcltech.com

Nitin Shukla, India
nitin-shukla@hcltech.com

Goodstack Unveils its All-in-One Impact Suite to Transform Corporate Giving and Social Impact

SAN FRANCISCO, April 22, 2025 /PRNewswire/ — Goodstack, the global leader in verifications for nonprofits, education, healthcare and social enterprises, has announced the launch of its all-in-one impact suite. This platform allows organizations to manage corporate grants, customer donations, workplace giving and volunteering, eliminating complexity and unifying all impact initiatives in one place.

Designed for scale and simplicity, Goodstack’s impact suite helps companies track, measure, and grow their programs without juggling multiple tools. Social impact teams can move beyond manual operations and focus on strategy, supported by automation, centralized reporting and actionable insights tailored to their goals.

A Unified Platform for Greater Impact

Goodstack’s flexible, all-in-one platform streamlines corporate social impact programs, making it easy to manage and measure impact globally. The platform offers four key solutions: corporate grants, customer donations, workplace giving and employee volunteering, all powered by industry-leading verification and global disbursement rails that enable rapid, accurate and transparent payments to nonprofits worldwide.

Global organizations like Atlassian, Canva and monday.com use Goodstack to confidently scale their impact—ensuring their programs are both efficient and deeply meaningful.

“We’re extremely excited to introduce our complete platform to the world,” said Henry Ludlam, CEO and founder of Goodstack. “Organizations have told us they need a single, powerful platform to manage and scale their impact efforts globally and locally, without the complexity of multiple systems. We built Goodstack’s suite to meet that need, ensuring businesses can maximize their social impact effortlessly.”

Key Solutions of the Goodstack Impact Suite:

  • Grants management to streamline your grant programs from application to impact reporting.
  • Customer donations to integrate customer-facing donation experiences directly into your checkout flow.
  • Workplace giving to enable donation matching, volunteering, fundraiser creation and employee rewards.
  • Employee volunteering to facilitate opportunity creation and skills-based match-making.
  • Verification to confirm eligibility and compliance of mission-driven organizations for in-kind and monetary donations.

Goodstack will showcase its corporate grants, customer donations, workplace giving and volunteering solutions at Engage for Good, April 22-24 in Palm Springs. Join us on April 24th at 11:30am for a featured session with Atlassian: Movers, Shakers, & Changemakers: Innovating Employee Engagement for Greater Impact.

For more information, visit goodstack.io.

Media Enquiries

For press inquiries, please contact us at pr@goodstack.io.

About Goodstack

Goodstack is revolutionizing corporate impact by enabling businesses to embed giving into everything they do. From employee giving and volunteering to grants management and customer donations, Goodstack’s platform makes it effortless to drive social good at scale. Headquartered in London, with offices in San Francisco, Denver and Sydney, Goodstack supports over 12 million causes worldwide through its extensive nonprofit and educational database.